1. Home
  2. CET vs NBTX Comparison

CET vs NBTX Comparison

Compare CET & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CET

Central Securities Corporation

HOLD

Current Price

$52.37

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo Nanobiotix S.A.

NBTX

Nanobiotix S.A.

HOLD

Current Price

$37.60

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CET
NBTX
Founded
1929
2003
Country
United States
France
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
CET
NBTX
Price
$52.37
$37.60
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
40.2K
80.4K
Earning Date
01-01-0001
03-31-2026
Dividend Yield
5.12%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$58.17
Revenue Next Year
N/A
N/A
P/E Ratio
$6.93
N/A
Revenue Growth
N/A
N/A
52 Week Low
$47.76
$4.93
52 Week High
$54.65
$57.14

Technical Indicators

Market Signals
Indicator
CET
NBTX
Relative Strength Index (RSI) 46.81 48.16
Support Level $52.23 $30.15
Resistance Level $52.52 $38.29
Average True Range (ATR) 0.64 2.36
MACD 0.02 0.05
Stochastic Oscillator 40.00 31.07

Price Performance

Historical Comparison
CET
NBTX

About CET Central Securities Corporation

Central Securities Corp is a non-diversified closed-end management investment company. The company's investment objective is long-term growth of capital. It invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.

About NBTX Nanobiotix S.A.

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

Share on Social Networks: